














Diurnal variation in the pharmacokinetics and brain distribution of morphine 






; Dirk-Jan van den Berg
2
; Johanna H. Meijer
1,3,*





Laboratory for Neurophysiology, Department of Molecular Cell Biology, Leiden University Medical 
Center, Leiden, the Netherlands;  
3
Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden, the 
Netherlands 
3
These authors share senior authorship 
 
*
Corresponding authors, contact details: 
- Prof. Dr. J.H. Meijer, Laboratory for Neurophysiology, Department of Molecular Cell Biology, 
Leiden University Medical Center, PO Box 9600 Mailbox S5-P, 2300 RC, Leiden, The 
Netherlands, Tel: +31 71 526 9760, Mail: J.H.Meijer@lumc.nl  
 
- Dr. E.C.M. de Lange, Division of Pharmacology, LACDR, Leiden University, PO Box 9502, 


















The pharmacokinetics and pharmacodynamics of drugs are influenced by daily fluctuations in 
physiological processes. The aim of this study was to determine the effect of dosing time on the 
pharmacokinetics and brain distribution of morphine. To this end, 4 mg/kg morphine was administered 
intravenously to Wistar rats that were either pre-treated with vehicle or tariquidar and probenecid to 
inhibit processes involved in the active transport of morphine. Non-linear mixed effects modelling was 
used to describe the concentration-time profiles of morphine and its metabolite M3G in plasma and 
brain tissue. We found that the concentrations of morphine in the brain and of M3G in plasma 
depended on the time of day, which could be quantified by a 24-hour rhythm in the efflux of morphine 
from brain tissue back into the circulation, with the lowest efflux during the two light-dark phase 
transitions with a difference between peak and trough of 20%. The active processes involved in the 
clearance of morphine and its metabolite M3G from plasma also showed 24-hour variation with the 
highest value in the middle of the dark phase being 54% higher than the lowest value at the start of 
the light phase. Hence, time of day presents a considerable source of variation in the 
pharmacokinetics of morphine, which could be used to optimize the dosing strategy of morphine.  
 



















Morphine is the most widely used opioid for the treatment of moderate to severe pain, despite the 
many side-effects associated with its use. Establishing a dosing regimen that results in adequate 
analgesia and minimal adverse side-effects is crucial, but this remains a challenge due to the high 
degree of intra- and interindividual variability associated with its pharmacokinetics and 
pharmacodynamics [1]. Time of day presents a considerable source of variation in the 
pharmacokinetics and pharmacodynamics of a wide variety of drugs due to daily rhythms in 
physiological processes [2].  
 
There are several indications that time of day influences morphine’s effect in both humans and animal 
models [3–14]. However, the physiological mechanisms that underlie these variations in morphine-
induced analgesia are unknown. To gain a more structured overview of the effect of time of drug 
administration on the therapeutic effect of morphine, it is essential to first determine 24-hour variation 
in both the plasma and brain pharmacokinetics of morphine. Although the effect of time of 
administration on the exposure to morphine has previously received some attention [15,16], these 
studies neither determined the 24-hour variation in the different pharmacokinetic parameters of 
morphine, nor did they address the 24-hour variation in its distribution to the brain, morphine’s main 
site of action.  
 
The concentration of morphine in blood and subsequently in the central nervous system depends on 
several processes, such as metabolism by UDP glucuronosyl transferase (UGT) 2B7 in the liver 
[17,18] and efflux transport by specialized transporters including P-glycoprotein and multi-drug 
resistance proteins (mrps) [1,19–21]. It has been shown that these physiological processes show 24-
hour variation [2,22,23].   
 
To determine 24-hour variation in the pharmacokinetic parameters of morphine, we used a study 
design in which morphine is intravenously administered to rats at six time-points during the 24-hour 
period combined with a pharmacokinetic modelling approach. Results from this study enhance our 

















2. Methods & Materials 
2.1 Animals 
Male Wister WU rats (Charles River, the Netherlands) were housed in groups for at least twelve days 
under standard environmental conditions (humidity 60%, ambient temperature 21
o
C) with food 
(Laboratory chow, Hope Farms, Woerden, The Netherlands) and water ad libitum. After surgery, 
animals were kept individually until the end of the experiment under otherwise similar conditions. The 
animal procedures were performed in accordance with the Dutch law on animal experimentation and 
were approved by the Animal Ethics Committee of the Leiden University (protocol number 
DEC14041). 
 
2.2 Study design 
Cannulation of the femoral artery and vein was performed as described previously [24]. Anesthesia 
was induced and maintained by respectively 5% and 1-2% isoflurane throughout the surgical 
procedures. Experiments were conducted seven days after surgery and started at one of six different 
time points (t =0 at either Zeitgeber time (ZT) 0, 4, 8, 12, 16 or 20, with ZT12 defined as the moment 
that lights are turned off). Experiments that took place during the dark phase were conducted under 
dim red light. At t= -25 min, tariquidar (15mg/kg; XR9576 from Avant pharmaceuticals, London, UK, in 
5% glucose) or vehicle (5% glucose) was administered for 10 minutes, followed by administration of 
probenecid (150mg/kg; Sigma-Aldrich, Zwijndrecht, the Netherlands, in 5% NaHCO3) or vehicle (5% 
NaHCO3) for 10 minutes. Half of the animals received a combination of tariquidar and probenecid 
(inhibitor-treated group); the other half received the two vehicle solutions (vehicle-treated group). At 
t=0, morphine HCl (4mg/kg in saline; Pharmachemie BV, Haarlem, the Netherlands) was administered 
for 10 minutes. The selection of this dose was based on previous research in our laboratory [25]. All 
drugs were administered intravenously using a syringe pump (Pump 22 Multiple Syringe Pump, 
Harvard Apparatus, Holliston, MA, USA). Plasma samples (150 µL) were collected at t=-5, 10, 20, 30, 
45, 60, 90 and 120 min as well as at t = 180 and/or 240 min, depending on when the experiment was 
terminated and stored at   -20
o
C until further analysis. At either t=120, 180 or 240 min, animals were 
euthanized by an overdose of Nembutal, transcardially perfused and decapitated. Brain tissue was 
removed, immediately placed on ice and subsequently stored at -80
o

















2.3 SPE-LC-MS/MS analysis 
Morphine and morphine-3-glucoronide (M3G) were measured in plasma and brain tissue using liquid 
chromatography tandem mass spectrometry (LC-MS/MS) (Methods S1).  
 
2.4 Data processing 
Samples below LLOQ (<1%) were marked in the data set but were retained, as described previously 
[26]. Concentrations (ng/mL) were converted to nanamol/mL using the molecular weight of 
morphine.HCl (321.8g/mol) and M3G (free base) (461.47g/mol). Based on protein binding values of 
morphine in rats that have been reported previously [27–31], an unbound fraction of 70% was used. 
The degree of plasma protein binding of M3G is very low (unbound fraction of 93% [27]) and was not 
taken into account in further analysis.  
 
2.5 Population pharmacokinetic model development 
A population pharmacokinetic model was developed to describe the concentration-time profiles of 
morphine and M3G in plasma and in morphine brain tissue using nonlinear mixed effects modelling 
(NONMEM 7.3 [32]) in combination with Pirana (v2.8.2), PsN (v3.7.6), Xpose (v4) and R (v3.1.2) [33].  
To compare the fit of nested models, the likelihood ratio test was used, under the assumption that the 
difference in -2 log-likelihood is χ
2
 distributed with degrees of freedom (d.f.) determined by the number 
of additional parameters in the more complex model. Hence, a decrease in Objective Function Value 
(OFV) of at least 3.84 points (p-value <0.05) with one additional parameter was considered to provide 
a significantly better fit of the data compared to its parent model. The fit of non-nested models were 
compared using the Akaike Information Criterion (AIC) [34].The first-order method with conditional 
estimation and interaction (FOCEI) and the ADVAN6 subroutine were used throughout model 
development. Model selection was based on OFV, precision and plausibility of parameter estimates, 
graphical evaluation of the goodness of fit and visual predictive checks (VPC). 
Interanimal variability was described using an exponential model. Additive, proportional and combined 
error models were considered to describe the residual variability [34]. Pre-treatment with probenecid 
and tariquidar was assumed to inhibit all active transport processes. Therefore, this effect was 
















𝑃 = 𝜃𝑝𝑎𝑠𝑠𝑖𝑣𝑒 + 𝜃𝑎𝑐𝑡𝑖𝑣𝑒 ∗ (1 − 𝑇𝑅𝑇)    Equation 1 
Where θpassive is the passive component of the clearance parameter, θactive is the active component of 
the clearance parameter and TRT is the treatment group (0 for vehicle-treated animals; 1 for inhibitor-
treated animals). The effect of the inhibitors on other (non-clearance) parameters was assessed as 
follows: 
𝑃 = 𝜃 ∗ 𝜃𝐼𝑁𝐻
𝑇𝑅𝑇     Equation 2 
Where θINH is the fractional change in parameter θ in the presence of inhibitor treatment.  
A sequential approach was used to develop the population PK model. Firstly, different structural 
models were considered (different number of peripheral compartments, linear or Michaelis-Menten 
clearance) to describe morphine and M3G concentrations in plasma. The volume of the M3G 
compartment was set equal to the volume of the central morphine compartment to yield a structurally 
identifiable model. In the second step, the morphine concentrations in brain tissue were added to the 
data set and the PK model was extended to describe the concentration profile in brain tissue. Lastly, 
the effect of time of day on the pharmacokinetic parameters was assessed. As an exploratory 
approach, the distribution of conditional weighted residuals with interaction (CWRESI) over time was 
investigated per treatment group. Subsequently, it was investigated whether the model fit could be 
improved by describing one or more parameters by a sinusoidal function with a principal period of 24-
hour and one or more harmonic terms (Equation 3). 
𝑃 = 𝜃𝑀𝑒𝑠𝑜𝑟 + ∑ [𝜃𝐴𝑚𝑝𝑙𝑖𝑡𝑢𝑑𝑒,𝑛 ∗ cos (
2𝜋∗𝑛∗(𝑡−𝜃𝜑,𝑛)
24
)]𝑁𝑛=1    Equation 3 
In this equation, θMesor represents the rhythm-adjusted mean value of the parameter, N is the total 
number of harmonics included in the model, θAmplitude,n is the amplitude of the n
th
 harmonic, θφ,n is the 
acrophase (time of peak in minutes after onset of light period) of the n
th
 harmonic and t is the time with 
t=0 defined as the onset of the light period.  
2.6 Simulations 
Two dosing regimens were simulated using the package deSolve (v1.11) in R: 1) a single 10min. 
















after onset of the light period and 2) a continuous infusion of 0.5mg/kg/h to a rat of 250g for 24 hours 
starting at 4 and 16 hours after the onset of the light period. 
 
3. Results 
3.1 Morphine and M3G pharmacokinetics in plasma 
Data from three animals were missing due to complications during surgery and data from four animals 
were missing due to difficulties with the cannulas during the experiment, so data from 89 animals 
(mean weight ± standard deviation: 269 ± 29g) were available for pharmacometric analysis. Table 1 
shows the number of animals per treatment group. Morphine and M3G concentrations in plasma are 
shown in upper and middle panels of Figure 1.  
 
The concentration-time profiles of morphine were described by a model consisting of a central 
compartment, one peripheral compartment and linear clearance from the body. To account for the 
difference in morphine pharmacokinetics between vehicle-treated animals and inhibitor-treated 
animals, the clearance of morphine from the body (CL10) was split into an active and a passive 
component as described in Equation 1, resulting in a significant improvement of the model fit (ΔOFV -
208, p<0.01, 1 d.f.) and reducing the interanimal variability on CL10 from 123% to 23%.  
 
It was found that the conversion of morphine to M3G showed concentration-dependent saturation that 
could be described by Michaelis-Menten kinetics (ΔOFV -402, p<0.01, 1 d.f.). Subsequent 
incorporation of interanimal variability and the effect of inhibitor treatment resulted in a model with 
interanimal variability included on CL10, the clearance of M3G from plasma (CLM3G), 
intercompartmental clearance (Q2) and the maximum conversion rate of morphine to M3G (Vmax).  
 
3.2 Morphine pharmacokinetics in brain tissue 
Morphine concentrations in brain tissue in vehicle-treated animals and inhibitor-treated animals at 
each of the six dosing times are shown in the lower panels of Figure 1. The plasma model was 
extended to describe these concentration-time profiles. The base model, consisting of one brain 
compartment and inter-compartmental clearance (QBR) to describe the transport to and from plasma, 
















subsequent modelling steps, it was found that a model that described the brain concentrations as 
deep brain concentrations that was indirectly linked to the central plasma compartment by a transit 
compartment referred to as the extra-cellular fluid (ECF) compartment, known as an important 
compartment for morphine distribution into the brain [35], could best describe the brain concentrations 
data. In the final brain model, drug transport between the deep brain compartment and the ECF 
compartment were described by a single clearance parameter and the flow between the ECF 
compartment and the plasma compartment by an influx parameter (QPL-ECF) and an efflux parameter 
that was split into a passive (QECF-PL,passive) and an active (QECF-PL,active) component (Figure 2). 
 
The volumes of the ECF and deep brain compartment were fixed to 1, because these values could not 
be estimated with sufficient precision. This model described the central trend and the variability in the 
brain concentrations well (Figure 3) and the residual unexplained variability reduced to 13%.  
 
3.3 Twenty-four hour variation in morphine pharmacokinetics 
The distribution of CWRESI of the morphine concentrations in brain of both vehicle and inhibitor-
treated animals showed clear time-of-day dependent bias with peaks around the light-dark transitions 
(Figure 4A). Inclusion of a two-harmonic cosine function with a 24-hour and 12-hour component on the 
efflux of morphine from the ECF compartment to plasma (QECF-PL) significantly improved the fit of the 
model (ΔOFV -16, p<0.005, 4 d.f.). This cosine function adequately removed this bias (Figure 4B), 
provided a better fit compared to implementation of a two-harmonic cosine function on the influx 
parameter (QPL-ECF) (AIC = -2.7)  and reduced the residual unexplained variability from 13.1% to 
11.9%. The 24-hour and 12-hour components of this cosine function had a peak at 22.8 hours and 5.9 
hours after lights on and relative amplitudes of 4.1% and 6.3%, respectively (Figure 5A). 
 
The CWRESI of morphine and M3G in plasma did not reveal a time-of-day dependent bias (Figure 4C 
and E). Nevertheless, inclusion of the same two-harmonic cosine with a 24-hour and 12-hour 
component on CLM3G,active and CL10,active significantly improved the fit of the model (ΔOFV -28, p<0.005, 
4 d.f.) and minimally affected the distribution of CWRESI over time-of-day (Figure 4D and F). The 24-
hour and 12-hour components of this cosine function had a peak at 18 hours and 7.6 hours after lights 

















In the final model (Run8202), the cosine function on QECF-PL was combined with the cosine functions 
on CLM3G,active and CL10,active. This model described the observed concentrations well (Figure 6). 
Parameter estimates from this model and from a bootstrap (500 runs) are shown in Table 2.  
 
3.4 Simulations 
The final model was used to perform simulations to show the impact of dosing time on the 
concentration profiles of morphine and M3G. Morphine concentrations in plasma after a single 
intravenous infusion are minimally affected by dosing time, while, morphine concentrations in brain 
tissue are influenced by dosing time with the highest concentrations attained 12 hours after the onset 
of the light period (Figure 7A). M3G concentrations were lowest and highest after administration at 4 
and 20 hours after the onset of the light period, respectively. During a continuous infusion at steady-
state, simulations indicate that morphine and M3G concentrations in plasma and morphine 
concentrations in brain fluctuate during the 24-hour period (Figure 7B). 
 
4. Discussion 
In this study, we have been able to characterize the effect of dosing time on processes that are 
involved in the distribution, metabolism and excretion of morphine through the development of a 
population pharmacokinetic model. By inhibiting P-gp and probenecid-sensitive transporters, the active 
and passive processes involved in the distribution and clearance of morphine could be investigated 
separately [20,21,25,29,36]. We find that the concentration profiles of morphine in brain tissue and of 
its metabolite M3G in plasma are affected by time of day. We show that the transport of morphine from 
brain tissue back into the circulation shows a characteristic 24-hour rhythm with the lowest efflux 
during the light-dark phase transitions. The active processes involved in the clearance of morphine 
and M3G from plasma also show 24-hour variation with the peak in the middle of the dark phase. 
These findings indicate that dosing time should be taken into account in the optimization of morphine’s 
dosing regimen. 
 
Our results show that inhibition of active transport processes by probenecid and tariquidar alters both 
















pharmacokinetics, inhibition of active transport reduced the systemic clearance of morphine, increased 
its intercompartmental clearance and lowered the maximal conversion rate of morphine to M3G. 
Because it was previously found that P-gp inhibition does not influence morphine concentrations in 
plasma [21,25,29,37], while probenecid treatment has been reported to reduce systemic morphine 
clearance and the formation of M3G in rats [20], we hypothesize that the systemic effects we observed 
are due inhibition of  multiple multidrug resistance proteins (mrps) in the kidney and liver [38–41] . 
 
Active transport inhibition also altered the brain distribution of morphine. Brain concentrations could be 
best described by a model in which a “deep brain” compartment was linked to the central plasma 
compartment by an extra-cellular fluid (ECF) compartment. An additional transport component that 
was absent inhibitor-treated animals was identified on the transport of morphine from the ECF 
compartment to plasma. This supports previous findings that morphine is subject to active efflux 
transport mediated by P-gp and probenecid-sensitive transporters [20,21,25,29,36]. 
 
Our findings indicate that several processes involved in morphine pharmacokinetics show 24-hour 
variation. It was previously shown in cancer patients that the maximal concentration (Cmax) and the 
area under concentration-time profile (AUC) at steady state are higher at 18:00 than at 10:00 and 
14:00 after oral administration [15]. In the present study, we have been able to quantify the relative 
contribution of the processes involved in the distribution, metabolism and elimination of morphine more 
precisely through the use of six dosing times and the development of a population pharmacokinetic 
model. We find that the active component of the systemic clearance of morphine and M3G show 24-
hour variation with a difference of 54% between the lowest value and the highest value. A 
physiological explanation of these findings could be the observation that the expression of various 
probenecid-sensitive transporters show 24-hour variation in the kidney [42]. However, future research 
to elucidate the underlying mechanisms is warranted.  
 
Furthermore, we find that the transport of morphine from the brain to the blood shows a 12-hour 
rhythm with the lowest values at the transitions of the light/dark phase. This rhythm could be described 
by a 24-hour and 12-hour sinusoidal function on this parameter with a difference between the highest 
















dependent bias observed in the conditionally weighted residuals. In a previous study we found that the 
efflux of the P-gp substrate quinidine from the brain to plasma is more than two-fold higher during the 
dark phase compared to the light phase in the presence of functional P-gp transport, but not when P-
gp transport is blocked [23]. In the present study, we do not find this P-gp dependent effect for 
morphine. While quinidine is a selective P-gp substrate, morphine has more complex transport 
mechanisms across the BBB, which is not only affected by P-gp but also by probenecid-sensitive 
transporters. The daily variation in P-gp activity may be (partly) counterbalanced by a differentially-
phased variation in probenecid-sensitive transporters. Hence, multiple mechanisms likely give rise to 
the 12-hour rhythm in the transport of morphine from the brain to blood.  
 
We performed simulations of a single intravenous dose and of a continuous infusion regimen to 
visualize the effect of the daily rhythmicity in morphine pharmacokinetics on the concentration-time 
profiles in plasma and brain tissue. Although morphine concentrations in plasma are minimally 
affected by dosing time, metabolite concentrations in plasma and morphine concentrations in brain 
tissue do depend on the time of day. This finding has several important implications: it indicates that 
time of day can be a substantial source of variation in the pharmacokinetics and, possibly, the 
pharmacodynamics of morphine when it is not properly accounted for, but also that these systematic 
variations could be exploited to optimize morphine’s dosing regimen.  
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Figure 1 Concentration profiles of morphine (MOR) in plasma (upper panels), M3G in plasma (middle 
panels) and MOR in brain tissue (lower panels) in vehicle-treated (left) and inhibitor-treated animals 
(right) after different dosing times.  
 
Figure 2: Structure of the final combined plasma-brain model. Colored compartments indicated the 
site of sampling (red: morphine concentrations in plasma; green: M3G concentrations in plasma; blue: 
morphine concentrations in brain tissue).  
 
Figure 3 Visual predictive check (VPC) stratified by treatment group. Dots: observed data; solid line: 
median of the predicted concentrations; shaded areas enclosed by dashed lines: 90% prediction 
intervals of the simulated data. 
 
Figure 4 Distribution of CWRESI vs time of dose in vehicle-treated (dark symbols) and probenecid 
(PRB) – tariquidar (TQD) treated (light symbols) animals. A, C, E: CWRESI distribution in the model 
without cosine functions of morphine concentrations in brain (A) and in plasma (C) and of M3G 
concentrations in plasma (E). B: CWRESI distribution in the model with a 24+12-hour cosine included 
on QECF-PL of morphine concentrations in brain. D and F: CWRESI distribution in the model with a 
24+12-hour cosine function included on CL10,active and CLM3G, active of morphine concentrations in 
plasma (D) and of M3G concentrations in plasma (F).  
 
Figure 5 Shape of the cosine functions included on QECF-PL (left), CL10,active (middle) and CLM3G,active 
(right).  
 
Figure 6 Measured versus population predicted (PRED; upper panels) and individual predicted 
(IPRED; lower panels) concentrations of morphine (MOR) in plasma (left, red), M3G in plasma 
(middle, green) and MOR in brain tissue (right, blue) of the final model. Dark coloured symbols 
represent vehicle-treated animals; light coloured symbols represent inhibitor-treated animals. Dotted 

















Figure 7 Simulations of morphine (MOR) concentration-time profiles in plasma (left), M3G 
concentrations in plasma (middle) and morphine concentrations in brain (right) after a 10 min. 
intravenous infusion of 4 mg/kg at six different dosing times (start of infusion at t=0, 4, 8, 12, 16, 20 
hours after light onset) (a) and during a continuous infusion of 1mg/kg/h started at 0 hours after light 

















































































































































Table 1 Number of animals per treatment group 
Dosing time No. of vehicle-treated animals No. of inhibitor-treated animals 
0 7 5 
4 8 7 
8 8 8 
12 8 7 
16 8 7 
20 8 8 


















Table 2 Parameter estimates of combined plasma and brain model (with 24-hour variation included on 
CL10,active, CLM3G,active and QECF-PL)  and results from bootstrap analysis (444/500 resamples successful) 




 CL10  mL/min 
CL10=θCL10,passive+CL1
0,active *  (1-TRT) 
θCL10,passive 4.97  4.4% 4.98 (4.63 - 5.35) 
  With CL10,active = 
θmesor * (1+θamp,24 * 
cos(2π * (t - 
θphase,24)/1440) + 
θamp,12 * cos(2π * ( t- 
θphase,12)/720)) 
θmesor 8.24  16.7% 8.19 (6.12 – 10.7) 
  θamp,24 (%) 12.3  46.3% 14.5 (5.61 – 25) 
  θphase,24 (min) 1070  11.8% 1053 (839 - 1240) 
  θamp,12 (%) 12.6%  42% 13.3 (5.17 – 22.6) 
  θphase,12 (min) 461  8.6% 463 (384 – 547) 
 V1  mL V1=θV1 θV1 109  16.3% 109 (80.6 - 144) 
 Q2  mL/min Q2 = θQ2 * θQ2,INH
TRT 
θQ2 11.0  8.9% 11.0 (9.25 – 12.4) 
θQ2,INH 1.52  5% 1.52 (1.40 – 1.67) 
 V2 mL V2=θV2 θV2 508  4.9% 505 (454 – 537) 
M3G plasma 
 Vm,MET  mL/min 




θVM 15.4  7.9% 15.5 (13.7 – 17.7) 
θVM,INH 0.443  11.7% 0.440 (0.358 – 0.539) 
 Km,MET  nmol/mL Km,MET=θKM θKM 0.325  18.4% 0.327 (0.250 – 0.490) 
 CLM3G mL/min 
CLM3G = 
θCLM3G,passive+CLM3G,act
ive * (1-TRT) 
θCLM3G,passive 2.8  15.4% 2.76 (2.14 – 3.51) 
    
  With CLM3G,active = 
θmesor * (1+θamp,24 * 
cos(2π * (t - 
θphase,24)/1440) + 
θamp,12 * cos(2π * ( t- 
θphase,12)/720)) 
θMesor 6.85 11.3% 6.83 (5.39 – 8.04) 
  θamp,24 (%) See CL10,active  
  θphase,24 (min) See CL10,active  
  θamp,12 (%) See CL10,active  
  θphase,12 (min) See CL10,active  
Morphine brain 
 VDBR  mL VDBR = θVDBR θVDBR 1 FIX   
















 VECF  mL VECF = θVECF θVECF 1 FIX   
 QECF-PL  mL/min 
QECF-PL = 
(θQECFPL,passive + 
QECFPL,active * (1-TRT)) 
* (1+θamp,24 * cos(2π * 
(t - θphase,24)/1440) + 
θamp,12 * cos(2π * ( t- 
θphase,12)/720)) 
θQECFPL,passive 0.0256  9.5% 0.0251 (0.0211 - 0.0301) 
θQECFPL,active 0.0834  12.4% 0.0824 (0.0659 – 0.103) 
  θamp,24 (%) 3.76%  42% 4.33 (1.75 – 6.82) 
  θphase,24 (min) 1390  7.4% 1390 (1150 – 1600) 
  θamp,12 (%) 6.33%  32.2% 6.76 (3.79 – 10.5) 
  θphase,12 (min) 1060  3.3% 1060 (990 – 1120) 
 QPL-ECF mL/min QPL-ECF = θQPLECF θQPLECF 0.0322  10.5% 0.0316 (0.260 – 0.0386) 
Inter-animal variability (CV%) 
 ω
2
 CL10  17.3 16.8 
 ω
2 
Vm,MET 22.2 21.9 
 ω
2 
CLMG 43.5 42.6 
 ω
2
 Q2 18.7 18.4 
 ω
2
 Vm,MET ~ ω
2 
CLMG (untransformed) 0.0761 0.0742 
Residual unexplained variability (%)  
 σPL 17.0 16.8 
 σM3G 14.5 14.4 
 σDBR 11.8 11.3 
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